RESUMEN
We report the case of a 53-year-old patient with a mitral prosthesis hospitalized for heart failure. Diagnosis of mitral prosthetic thrombosis, led to a therapeutic disjunction between thrombolysis and surgery. Because of the high risk of surgical intervention, the patient was treated with r-TPA (accelerated infusion), showing immediate, successful response.
Asunto(s)
Prótesis Valvulares Cardíacas , Válvula Mitral , Terapia Trombolítica , Trombosis/tratamiento farmacológico , Activador de Tejido Plasminógeno/administración & dosificación , Femenino , Humanos , Persona de Mediana Edad , Proteínas Recombinantes/administración & dosificación , Factores de TiempoRESUMEN
La angina de pecho es la forma más común de manifestarse la cardiopatía isquémica. El paciente que presenta dolor anginoso es afortunado porque dentro del amplio abanico de manifestaciones de la cardiopatía isquémica, cualquiera de las otras como infarto de miocardio, muerte súbita, insuficiencia cardíaca y arritmias ventriculares, son más graves y porque, además, la presencia del dolor torácico permite poner en marcha todo el sistema diagnósticoterapéutico que redundará finalmente en una reducción del infarto de miocardio y la muerte. El tratamiento de la angina de pecho, tanto en su forma crónica y estable como en la forma aguda e inestable, tiene como objetivos inmediatos controlar el síntoma y prevenir la muerte y el infarto agudo, y como objetivos a medio y largo plazo el control de la enfermedad aterosclerótica coronaria. El plan terapéutico siempre deberá diseñarse según el perfil de riesgo de cada paciente.La angina inestable frecuentemente se estabiliza con tratamiento médico, pero puede presentar inicialmente predictores de mal pronóstico o en la fase pre-alta hospitalaria una prueba de isquemia moderada o severamente positiva, que determinarán una actitud agresiva con angiografía coronaria y eventualmente revascularización. En la angina crónica, el tratamiento médico, que se dirige a controlar síntomas pero también a prevenir infarto y muerte, debe también configurarse atendiendo a tres variables de significación pronóstica, grado de isquemia, estado de la función ventricular y extensión angiográfica de la enfermedad coronaria. Según el perfil pronóstico de cada paciente se decidirá el tipo de tratamiento definitivo. Los casos con mayor riesgo se beneficiarán de un tratamiento revascularizador y la técnica a proponer se establecerá en función de la localización y extensión de las lesiones anatómicas, la severidad de la i quemia y el grado de disfunción ventricular. (AU)
Asunto(s)
Humanos , Angina de Pecho/terapia , Pronóstico , Medición de Riesgo , Factores de RiesgoRESUMEN
INTRODUCTION AND OBJECTIVES: The increase of mean platelet volume in the late phase of myocardial infarction is an independent predictor for recurrent myocardial infarction and death, but the association between this finding and the short-term prognosis after acute myocardial infarction is unknown. The goals of this study were to assess the influence of mean platelet volume on the risk of death, recurrent ischemic events or cardiac heart failure during the in-hospital phase of myocardial infarction and to analyse the relationship between mean platelet volume and several demographic and clinical variables registered on admission. MATERIAL AND METHODS: A population of 1,082 patients with acute myocardial infarction were distributed in two groups according to the platelet volume measured on admission: group 1, mean platelet volume > 9 fl (n = 443) and group 2, mean platelet volume < or = 9 fl (n = 639). The difference between both groups on the end-point of this study were assessed by univariate and multivariate statistical methods. An univariate analysis was also applied to assess the relationship between platelet volume and the baseline variables. RESULTS: A mean platelet volume > 9 fl was associated with a significant increase of risk for the combined end-point considered (OR = 1.37; p = 0.026). By univariate analysis, an increased platelet volume was related to a higher risk of cardiac failure (OR = 1.46; p = 0.01) and a non-significant increase in the incidence of recurrent ischemic events (OR = 1.35; p = 0.07). In addition, a large platelet volume was also associated with a higher prevalence of prior myocardial infarction, arterial hypertension and diabetes mellitus. CONCLUSIONS: The results of this study suggest that the increase of mean platelet volume on admission is an independent risk factor for cardiac heart failure and is associated with a non significant higher rates of ischemic events during the recovery phase of acute myocardial infarction.
Asunto(s)
Infarto del Miocardio/sangre , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Infarto del Miocardio/mortalidad , Recuento de Plaquetas , Pronóstico , España/epidemiología , Factores de TiempoRESUMEN
INTRODUCTION: The analysis of heart rate variability has been accepted as a non-invasive method to evaluate the influence of the autonomic nervous system over the heart. Although heart rate variability has been used during the last decade in several illnesses the studies in hypertrophic cardiomyopathy are scarce. OBJECTIVES: We report the activity of the autonomic nervous system in patients with hypertrophic cardiomyopathy using the analysis of heart rate variability. PATIENTS AND METHODS: Heart rate variability was evaluate by the analyzing 24-h ambulatory electrocardiograms (Holter) in 20 patients with hypertrophic cardiomyopathy and in 15 controls. This method has been used to measure heart rate variability. Spectral analysis of the frequencies were calculated using fast Fourier transformation. Spectral heart rate variability was computed as high (0.15 to 0.40 Hz) low (0.04 to 0.15 Hz) and total (0.01 to 1.0 Hz). We compared the relation between low/high frequency as an index of the sympathetic/parasympathetic balance. All data are expressed as mean value +/- SD. The unpaired Student t-test was used. A two tailed p valued < 0.05 was considered statistically significant. RESULTS: There were no differences in the mean heart rates among the patients with hypertrophic cardiomyopathy and normal subjects (mean +/- SD: 71 +/- 9 versus 74 +/- 11 beats/minute; p = NS) while there was a significant decline in total spectral (mean +/- SD: 7.14 +/- 1.1 versus 7.57 +/- 0.6 ln [ms2]; p = 0.02) and high (mean +/- SD: 5.22 +/- 0.8 versus 5.63 +/- 1.3 ln [ms2]; p = 0.04) as well as in low spectral frequency of heart rate variability (mean +/- SD: 22 +/- 0.8 versus 5.63 +/- 1.3 ln [ms2]; p = 0.04) in patients with hypertrophic cardiomyopathy. There were no differences in the low/high frequency component ratio in these patients (mean +/- SD: 1.1 +/- 0.1 versus 1.2 +/- 0.1 ln [ms2]; p = NS). CONCLUSIONS: These facts suggest that the patients with hypertrophic cardiomyopathy have an alteration in the autonomic nervous system: sympathetic (low spectral frequencies) and parasympathetic activity (high spectral frequencies), although this does not reflect an imbalance between sympathetic and parasympathetic activities (relation of low to high spectral frequencies).